CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-06 | Zuga Matt CFO & Chief Business Officer | Sale | −5,100 | $1.97 | $10K | 222,644 |
| 2026-01-06 | Siemers Eric Chief Medical Officer | Sale | −6,834 | $1.97 | $13K | 159,464 |
| 2026-01-06 | OConnell Daniel Joseph Chief Executive Officer | Sale | −5,102 | $1.97 | $10K | 657,737 |
| 2026-01-06 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | −7,097 | $1.97 | $14K | 150,030 |
| 2026-01-06 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | −3,801 | $1.97 | $7K | 146,229 |
| 2026-01-06 | Barton Russell Chief Operating Officer | Sale | −3,618 | $1.97 | $7K | 128,499 |
| 2026-01-05 | Zuga Matt CFO & Chief Business Officer | Sale | −4,000 | $1.96 | $8K | 227,744 |
| 2026-01-05 | Siemers Eric Chief Medical Officer | Sale | −4,000 | $1.96 | $8K | 166,298 |
| 2026-01-05 | OConnell Daniel Joseph Chief Executive Officer | Sale | −4,649 | $1.97 | $9K | 662,839 |
| 2026-01-05 | Meisner Derek M Chief Legal Officer & Corp Sec | Sale | −4,000 | $1.96 | $8K | 157,127 |
| 2026-01-05 | Barton Russell Chief Operating Officer | Sale | −4,000 | $1.96 | $8K | 132,117 |
| 2025-11-06 | Golumbeski George Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-06-04 | Stoppel Laura Director | Grant or award | +12,800 | 12,800 | ||
| 2025-06-04 | Stoppel Laura Director | Grant or award · Stock Option (right to buy) | +19,500 | 19,500 | ||
| 2025-06-04 | Stalfort John A III Director | Grant or award | +12,800 | 185,124 | ||
| 2025-06-04 | Stalfort John A III Director | Grant or award · Stock Option (right to buy) | +19,500 | 19,500 | ||
| 2025-06-04 | Drapkin Kimberlee C Director | Grant or award | +12,800 | 12,800 | ||
| 2025-06-04 | Drapkin Kimberlee C Director | Grant or award · Stock Option (right to buy) | +19,500 | 19,500 | ||
| 2025-06-04 | Fountain Nathan B Director | Grant or award | +12,800 | 19,050 | ||
| 2025-06-04 | Fountain Nathan B Director | Grant or award · Stock Option (right to buy) | +19,500 | 19,500 |
Page 5 of 13 · 246 trades